Health Equity and the Cost of Novel Treatments for Alzheimer’s Disease and Related Dementias
NIA R61 / R33 - July 1, 2022
Supports R61 / R33 research projects to address health equity, drug costs, and access to new therapeutics or repurposed drugs for Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). Projects must identify preferences for pharmacological treatment among racial and ethnic minority people living with AD/ADRD, assess whether cost barriers to pharmacological care exist for racial and ethnic minority people living with AD/ADRD, and quantify expenditures and health-related quality of life (HRQoL) among people interested in receiving novel or repurposed drugs for AD/ADRD.
Deadline: July 1, 2022